Kenvue Inc.
- Industry
- Household & Personal Care
- Exchange
- US
- Country
- USA
- IPO date
- May 4, 2023
- Employees
- 21,780
- Website
- www.kenvue.com
Composite valuation range · conservative $10–$13 / fair $16–$20 / optimistic $22–$26. At $18.12, Within the fair intrinsic-value range.
At publication $17.69 (May 28, 2026)
No reports on this stock in your language yet.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
History
Coming soonThis section is being filled in — check back soon.
Industry position
Coming soonThis section is being filled in — check back soon.
